# Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases

> **NCT07343479** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Zhejiang Cancer Hospital** · enrollment: 45 (estimated)

## Conditions studied

- NSCLC (Advanced Non-small Cell Lung Cancer)
- EGFR Gene Mutations
- Brain Metastasis

## Interventions

- **DRUG:** sac-TMT plus EGFR-TKI

## Key facts

- **NCT ID:** NCT07343479
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2027-06-20
- **Final completion:** 2029-12-20
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-01-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07343479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07343479, "Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07343479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*